![Roger Tell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Roger Tell
Directeur Technique/Scientifique/R&D chez
ISOFOL MEDICAL AB
Profil
Roger Tell is currently the Director at Vivesto AB since 2022 and the Chief Scientific & Medical Officer at Isofol Medical AB since 2019.
Previously, he worked as the Vice President-Clinical Development at Aprea Therapeutics AB. Dr. Tell obtained his doctorate degree from Karolinska Institutet in 1998.
Postes actifs de Roger Tell
| Sociétés | Poste | Début |
|---|---|---|
| ISOFOL MEDICAL AB | Directeur Technique/Scientifique/R&D | 01/02/2019 |
| VIVESTO AB | Directeur/Membre du Conseil | 25/05/2022 |
Anciens postes connus de Roger Tell
| Sociétés | Poste | Fin |
|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Corporate Officer/Principal | 01/02/2019 |
Formation de Roger Tell
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
12
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivesto AB
 Vivesto AB Pharmaceuticals: GenericHealth Technology Develops cancer drugs based on nanotechnology for human and veterinary use | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Isofol Medical AB
 Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products | Health Technology |
